Results 191 to 200 of about 42,337 (292)

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics

MedComm – Oncology, Volume 4, Issue 3, September 2025.
Immune checkpoints in tumor immunotherapy. Ligand binding to the receptor inhibits immune cell function, promotes tumor cell immune escape, and suppresses the immune response. The pathways of action are VISTA‐IGSF11, TIM‐3‐Ceacam1, CD47‐SIRPα, CTLA‐4‐CD80/CD86, PD‐L1‐PD‐1, MHC‐1‐LILRB, and CD24 ‐ Siglec ‐10. There are also other immune checkpoints such
Han Sun, Dan Huang, Huiling Zhang, Mingyuan Dong, Simiao Wang, Man Sun, Jiayi Liu, Yiqi Wang, Xiaojie Qu, Xuefeng Li, Zhaogang Yang   +10 more
wiley   +1 more source

A Scoping Review on Cognition in Myelodysplastic Syndromes: Advances and Challenges. [PDF]

Med Sci (Basel)
Tsiakiri A, Frigkas K, Vlotinou P, Papoutselis M, Christidi F, Karavasilis E, Kotsianidis I, Kourkoutsakis N, Vadikolias K, Liapis K.   +9 more
europepmc   +1 more source

Concurrent Inflammatory Bowel Disease and Myelodysplastic Syndromes

, 1999
Gavin C. Harewood, Edward V. Loftus, Ayalew Tefferi, William J. Tremaine, William J. Sandborn   +4 more
openalex   +1 more source

Classical and Late‐Onset SOS/VOD After Allogeneic HSCT: A Japanese Transplant Registry Analysis

American Journal of Hematology, Volume 100, Issue 8, Page 1283-1294, August 2025.
ABSTRACT Sinusoidal obstruction syndrome/veno‐occlusive disease (SOS/VOD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (allo‐HSCT). According to the 2016 European Society for Blood and Marrow Transplantation criteria, SOS/VOD is classified into classical SOS/VOD and late‐onset SOS/VOD, but their similarities and ...
Kyoko Masuda, Keisuke Kataoka, Masatoshi Sakurai, Yuho Najima, Naonori Harada, Shoko Ukita, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Masatsugu Tanaka, Hiroyuki Ohigashi, Jun Ishikawa, Satoshi Yoshihara, Masashi Sawa, Shuichi Ota, Yoshinobu Kanda, Tetsuya Nishida, Makoto Onizuka, Yoshiko Atsuta, Hideki Nakasone, Kimikazu Yakushijin   +20 more
wiley   +1 more source

Molecular characteristics and clinical implications of TP53 mutations in therapy-related myelodysplastic syndromes. [PDF]

Blood Cancer J
Bao Z, Li B, Qin T, Xu Z, Qu S, Jia Y, Li C, Pan L, Gao Q, Jiao M, Wang H, Sun Q, Xiao Z.   +12 more
europepmc   +1 more source

Expression of inducible nitric oxide synthase (NOS) in bone marrow cells of myelodysplastic syndromes

, 1999
Masanobu Kitagawa, Makoto Takahashi, S Yamaguchi, M. Inoue, Satoshi Ogawa, K. Hirokawa, Ryuichi Kamiyama   +6 more
openalex   +1 more source

Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease [PDF]

, 1998
Conor McCarthy, Susan Sheldon, Charles W. Ross, W. Joseph McCune   +3 more
openalex   +1 more source

Cohesins: Crossroad Between Cornelia de Lange Spectrum and Cancer Predisposition

American Journal of Medical Genetics Part A, Volume 197, Issue 8, August 2025.
ABSTRACT The cohesin complex plays crucial roles in DNA repair, chromatid separation, and gene transcription regulation. Pathogenic variants in cohesins or dysfunctional transcriptional regulators lead to cohesinopathies, a broader group of disorders including Cornelia de Lange Spectrum (CdLSp), for which the prevalence of cancer cases remains unclear.
Laura Rigotti, Stefano Rebellato, Antonella Lettieri, Silvia Castiglioni, Milena Mariani, Simona Totaro, Claudia Saitta, Cristina Gervasini, Grazia Fazio, Valentina Massa, Giovanni Cazzaniga, Angelo Selicorni   +11 more
wiley   +1 more source

Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances. [PDF]

Cancers (Basel)
Thalambedu N, Mohan Lal B, Harbaugh B, Alapat DV, Gaddam M, Gentille Sanchez CG, Kumaran M, Varma A.   +7 more
europepmc   +1 more source

Impact of COVID‐19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase

Cancer Medicine, Volume 14, Issue 15, August 2025.
ABSTRACT Background The COVID‐19 pandemic significantly increased mortality risks for individuals with hematological malignancies. Patients and Methods We conducted a single‐center observational study, focusing on the late pandemic phase of the infection (2022–2023), to identify risk factors associated with COVID‐19 outcomes in vaccinated patients with
Daniele Caracciolo, Giuseppe D'Aquino, Caterina Froio, Caterina Romeo, Vincenzo Bosco, Giulia Pensabene, Ludovica Tedesco, Pierosandro Tagliaferri, Pierfrancesco Tassone   +8 more
wiley   +1 more source